title: Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).
abstract: In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of 1-year target lesion failure. This study reports the 3-year outcomes. Patients (n=1,530) with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter≥2.50 mm to ≤4.25 mm and length≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. Three-year follow-up was available in 93.9% (703 of 749) of patients with CoCr-EES and 96.7% (733 of 758) of patients with PtCr-EES. Comparing CoCr-EES with PtCr-EES, 3-year rates of death (4.3% vs 3.7%, hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.52 to 1.48, p=0.62), cardiac death (1.9% vs 1.2%, HR 0.63, 95% CI 0.27 to 1.45, p=0.27), myocardial infarction (2.5% vs 2.3%, HR 0.92, 95% CI 0.48 to 1.79, p=0.81), ischemia-driven target lesion revascularization (4.9% vs 3.5%, HR 0.72, 95% CI 0.43 to 1.20, p=0.21), and Academic Research Consortium definite or probable stent thrombosis (0.5% vs 0.7%, HR 1.23, 95% CI 0.33 to 4.57, p=0.76) were not significantly different. In conclusion, 3-year results of the PLATINUM randomized, controlled, clinical trial demonstrate comparable safety and efficacy outcomes of the PROMUS Element PtCr-EES and the XIENCE V CoCr-EES.
authors: MonashHeart, Monash Health, Monash Medical Centre, Clayton, Victoria, Australia. Electronic address: ian.meredith@myheart.id.au.
authors: Ian T
authors: IT
authors: Meredith
authors: Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.
authors: Paul S
authors: PS
authors: Teirstein
authors: Princeton Baptist Medical Center, Birmingham, Alabama.
authors: Alain
authors: A
authors: Bouchard
authors: Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse, France.
authors: Didier
authors: D
authors: Carrié
authors: Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany.
authors: Helge
authors: H
authors: Möllmann
authors: West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom.
authors: Keith G
authors: KG
authors: Oldroyd
authors: The Heart Center, St. Vincent's Hospital, Indianapolis, Indiana.
authors: Jack
authors: J
authors: Hall
authors: Boston Scientific Corporation, Natick, Massachusetts.
authors: Dominic J
authors: DJ
authors: Allocco
authors: Boston Scientific Corporation, Natick, Massachusetts.
authors: Keith D
authors: KD
authors: Dawkins
authors: Cardiovascular Research Foundation, Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York.
authors: Gregg W
authors: GW
authors: Stone
mesh_terms: D002858:Chromium Alloys; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery*; D004311:Double-Blind Method; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000379:methods*; D017671:Platinum Compounds; D011474:Prosthesis Design; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002858:Chromium Alloys; D007166:Immunosuppressive Agents; D017671:Platinum Compounds; D000068338:Everolimus; D020123:Sirolimus